207296-89-7

Basic information

• Product Name: 4-Benzyloxycarbonylaminopiperidine Hydrochloride
• Synonyms: 4-Benzyloxycarbonylaminopiperidine Hydrochloride;4-(Cbz-aMino)piperidine Hydrochloride;4-BenzyloxycarbonylaMinopiperidine HCl;4-Piperidinyl-carbaMic Acid Benzyl Ester Hydrochloride;4-Piperidinyl-carbaMic Acid PhenylMethyl Ester Hydrochloride;4-(CBZ-AMINO)-PIPERIDINE HCL;BenzyloxycarbonylaMinopiperidine hydrochloride;benzyl N-(4-piperidyl)carbaMate hydrochloride
• CAS NO: 207296-89-7
• Molecular Formula: C13H19ClN2O2
• Molecular Weight: 270.75516
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 207296-89-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly, Heated), DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 4-Benzyloxycarbonylaminopiperidine Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzyloxycarbonylaminopiperidine Hydrochloride(207296-89-7)
• EPA Substance Registry System: 4-Benzyloxycarbonylaminopiperidine Hydrochloride(207296-89-7)

Safety Data

• Hazardous Substances Data: 207296-89-7(Hazardous Substances Data)

Usage

Description

4-Benzyloxycarbonylaminopiperidine Hydrochloride is an organic compound with the chemical formula C22H28ClN3O2. It is an off-white solid and is commonly utilized in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
4-Benzyloxycarbonylaminopiperidine Hydrochloride is used as an intermediate in the preparation of certain antibiotics for its ability to contribute to the development of effective treatments against bacterial infections.
Used in Biochemical Research:
In the field of biochemical research, 4-Benzyloxycarbonylaminopiperidine Hydrochloride is used as a building block for the synthesis of p-38 kinase inhibitors. These inhibitors play a crucial role in studying and managing cellular responses related to inflammation and apoptosis.
Used in Neuropharmacology:
4-Benzyloxycarbonylaminopiperidine Hydrochloride is also utilized as a precursor in the development of serotonin antagonists. These antagonists are essential in neuropharmacology for understanding and treating various neurological and psychiatric disorders related to serotonin dysregulation.

InChI:InChI=1/C13H18N2O2.ClH/c16-13(15-12-6-8-14-9-7-12)17-10-11-4-2-1-3-5-11;/h1-5,12,14H,6-10H2,(H,15,16);1H

Upstream product

• 182223-53-6 benzyl 1-benzylpiperidin-4-ylcarbamate 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 501-53-1 benzyl chloroformate 
• 220394-97-8 4-(benzyloxycarbonylamino)-1-(tert-butoxycarbonyl)piperidine 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 

Relevant articles and documents

Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria

We have previously reported amidopiperidine derivatives as a novel peptide deformylase (PDF) inhibitor and evaluated its antibacterial activity against Gram-positive bacteria, but poor pharmacokinetic profiles have resulted in low efficacy in in vivo mouse models. In order to overcome these weaknesses, we newly synthesized aminopiperidine derivatives with remarkable antimicrobial properties and oral bioavailability, and also identified their in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and penicillin-resistant Streptococcus pneumoniae (PRSP).

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g.,leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. (I)

QUINAZOLINE INHIBITORS OF PI3K

The invention is directed to compounds of formula I: and pharmaceutically acceptable salts as well as methods of making and using the compounds to inhibit PI3K.